Want to see NMTC full AI Analyst Report?
NMTC Stock Chart & Stats
$2.16
-$0.15(-7.89%)
At close: 4:00 PM EDT
$2.16
-$0.15(-7.89%)
Day’s Range― - ―
52-Week Range$0.96 - $6.96
Previous CloseN/A
Volume16.98K
Average Volume (3M)588.98K
Market Cap
$8.97M
Enterprise Value$24.70
Total Cash (Recent Filing)$2.05M
Total Debt (Recent Filing)$73.32K
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Dec 16, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding9,105,763
10 Day Avg. Volume159,219
30 Day Avg. Volume588,979
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)5.04
Price to Sales (P/S)2.95
P/FCF Ratio-12.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.27Price Target Upside236.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.59
Revenue Forecast (FY)$13.33M
Bulls Say, Bears Say
Bulls Say
Strong Revenue ScalingRapid revenue expansion indicates growing adoption of NeuroOne’s neurological procedure products and a broader commercial base. Continued top-line scaling could improve operating leverage over time, although the company must still convert this growth into sustainable profitability.
Low LeverageMinimal debt limits refinancing and solvency pressure, preserving flexibility while NeuroOne invests in product development and commercialization. A lightly leveraged balance sheet can help the company withstand operating volatility better than a debt-heavy structure, despite ongoing losses.
StereoCED Platform ProgressSuccessful large-animal procedures provide technical validation for StereoCED’s combined drug-delivery and electrophysiological-monitoring workflow. Progress toward human studies and expected fiscal Q4 2026 research-program revenue could broaden NeuroOne’s product pipeline and future revenue opportunities.
Bears Say
Deep Operating LossesSevere operating and net losses show that current expenses substantially exceed the gross profit generated by the expanding revenue base. Unless NeuroOne achieves meaningful operating leverage, continued losses could constrain investment capacity and prolong dependence on external funding.
Worsening Cash BurnLarge and worsening cash outflows indicate that commercial growth is not yet self-funding the business. Persistent cash consumption raises the resources required to support operations, development, and clinical progress, making future financial sustainability dependent on improved cash conversion.
Eroding Equity CushionThe shrinking equity base reduces the balance-sheet cushion available to absorb continued operating losses and fund development. If losses persist, NeuroOne’s financial flexibility may weaken further, potentially limiting its ability to pursue growth initiatives without additional capital.
NeuroOne Medical Technologies News
NMTC FAQ
What was NeuroOne Medical Technologies’s price range in the past 12 months?
NeuroOne Medical Technologies lowest stock price was $0.96 and its highest was $6.96 in the past 12 months.
What is NeuroOne Medical Technologies’s market cap?
NeuroOne Medical Technologies’s market cap is $8.97M.
When is NeuroOne Medical Technologies’s upcoming earnings report date?
NeuroOne Medical Technologies’s upcoming earnings report date is Dec 16, 2026 which is in 73 days.
How were NeuroOne Medical Technologies’s earnings last quarter?
NeuroOne Medical Technologies released its earnings results on Aug 19, 2026. The company reported -$0.23 earnings per share for the quarter.
Is NeuroOne Medical Technologies overvalued?
According to Wall Street analysts NeuroOne Medical Technologies’s price is currently Undervalued.
Does NeuroOne Medical Technologies pay dividends?
NeuroOne Medical Technologies does not currently pay dividends.
What is NeuroOne Medical Technologies’s EPS estimate?
NeuroOne Medical Technologies’s EPS estimate is -0.22.
How many shares outstanding does NeuroOne Medical Technologies have?
NeuroOne Medical Technologies has 9,105,763 shares outstanding.
What happened to NeuroOne Medical Technologies’s price movement after its last earnings report?
NeuroOne Medical Technologies reported an EPS of -$0.23 in its last earnings report. Following the earnings report the stock price went up 15.957%.
Which hedge fund is a major shareholder of NeuroOne Medical Technologies?
Currently, no hedge funds are holding shares in NMTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
NMTC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call delivered strong operational and clinical progress — including double-digit revenue growth (+16% YoY), 43% growth in orders, improved gross margins (+6.0 percentage points), ISO 13485 certification, and meaningful advances across product lines (OneRF, Trigeminal, StereoCED, BVNA). However, these positives are balanced by material near-term challenges: manufacturing lead times and backlog that constrain revenue recognition, rising operating expenses and widening net loss, and a significant decline in cash and working capital that creates liquidity pressure. Management has mitigation plans (second manufacturing site, ATM raises, supply acceleration) and clear clinical/regulatory milestones, but the financial and execution risks temper the upside from operational wins.View all NMTC earnings summariesNMTC Stock 12 Month Forecast
Average Price Target
$7.27
▲(236.42% Upside)